Skip to main content
MDF Exterior

ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.

Earth Day

Tackling the climate crisis and achieving an equitable clean energy future are among the biggest challenges of our time. 

An artist's rendering of the Ultium Cells battery cell production facility to be built in Spring Hill, Tennessee, which will employ 1,300 people. Recognizing the unique expertise of their organizations, ORNL, TVA, and the Tennessee Department of Economic and Community Development have been working together for several years to bring startups developing battery technologies for EVs and established automotive firms to Tennessee. Credit: Ultium Cells

ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.

ORNL’s Brenda Pracheil, left, and Kristine Moody collect water samples at Melton Hill Lake using a sophisticated instrument that collects DNA in the water to determine fish species and number of fish in the water, which could prove useful for monitoring hydropower impacts. Credit: Carlos Jones, ORNL/U.S Dept. of Energy

Researchers at Oak Ridge National Laboratory are using a novel approach in determining environmental impacts to aquatic species near hydropower facilities, potentially leading to smarter facility designs that can support electrical grid reliability.

Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals. Credit: ORNL, U.S. Dept. of Energy

Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.

Researchers studying secondary metabolites in the fungus Aspergillus flavus, pictured, found unique mixes of metabolites corresponding to genetically distinct populations. The finding suggests local environmental conditions play a key role in secondary metabolite production, influencing the discovery of drugs and other useful compounds. Credit: Tomás Allen Rush/ORNL, U.S. Dept. of Energy.

Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in

Peter Thornton, right, works with Robertsville Middle School students to assemble the RamSat. Credit: Ian Goethert/ORNL, U.S. Dept. of Energy

RamSat’s mission is to take pictures of the forests around Gatlinburg, which were destroyed by wildfire in 2016. The mission is wholly designed and carried out by students, teachers and mentors, with support from numerous organizations, including Oak Ridge National Laboratory.

Belinda Akpa applies her diverse expertise and high-performance computing to accelerate the drug discovery process and increase the chances of success when candidate molecules go to clinical trials. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

ATOM logo

The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.